Overview

Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer

Status:
Completed
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
Donafenib for advanced 131I-refractory/resistant differentiated thyroid cancer(DTC).
Phase:
Phase 2
Details
Lead Sponsor:
Suzhou Zelgen Biopharmaceuticals Co.,Ltd